Quthero develops a bioengineered wound management gel utilizing its proprietary Q-peptide technology, derived from Angiopoietin-1, to enhance cell migration and collagen deposition for faster healing. This gel effectively reduces inflammation and improves skin quality in post-aesthetic procedures, addressing the need for efficient wound care in dermatology.
Funding
$1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OCFounders
Product
Problem
Post-aesthetic procedures often result in inflammation, redness, swelling, bruising, and slow healing, impacting patient satisfaction and recovery time. Current wound-healing solutions may not adequately address these issues or fully support skin regeneration.
Solution
Quthero develops bioengineered regenerative therapies, based on its proprietary Q-peptide technology derived from Angiopoietin-1, to accelerate wound healing and improve skin quality. The Q-peptide promotes cell migration, collagen deposition, and blood vessel stabilization while reducing inflammation. Quthero's products are designed for post-aesthetic procedures to minimize redness, swelling, and bruising, leading to faster recovery and enhanced skin texture.
Target Audience
Quthero's products target individuals undergoing aesthetic procedures, dermatologists, and medical professionals seeking advanced wound-healing solutions.
Features
- Q-peptide technology: A synthetic, bioactive peptide sequence derived from Angiopoietin-1.
- Promotes cell adhesion, migration, and proliferation for tissue repair and regeneration.
- Supports blood vessel stabilization to regenerate blood supply in damaged tissues.
- Reduces cell death in environments prone to apoptosis.
- Clinically proven to reduce redness, swelling, and bruising post-aesthetic procedure.
- Accelerates healing and improves overall skin quality.